LOGIN  |  REGISTER
Astria Therapeutics
Astria Therapeutics

Natera to Participate in Upcoming Investor Conferences

September 01, 2023 | Last Trade: US$160.12 1.03 -0.64

AUSTIN, Texas / Sep 01, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:

  • The Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11 at 4:55 p.m. ET in New York, NY
  • The Baird 2023 Global Healthcare Conference on Tuesday, Sept. 12 at 4:20 p.m. ET in New York, NY

A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at investor.natera.com. Replays will be available shortly thereafter.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Astria Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page